This webinar will examine the EU, USA, and China recent FTAs and their impact, including on public health.
- Ruth Okediji, Harvard University
- Sean Flynn, American University – Washington – The US position at the TRIPS waiver, USTR's pressure and the issue of copyrights
- Carlos M. Correa - Special Section 301: US Interference with the Design and Implementation of National Patent Laws
- Ellen 't Hoen, Medicines Law and Policy & Global Health Law Group, Law Faculty, University of Groningen – EU TRIPS Plus demands in FTAs
- Peter Yu, Texas A&M - China's IP System between RCEP, CAI and CTPPP
Themes to be discussed:
- What is 'new' and what is a 'continuation' of previous positions, norms, and negotiating patterns deployed by the USA, EU, and China in trade and investment agreements? What is their potential impact on the issue of access to medical products?
- How does this new landscape affect negotiations and the position of developing countries, both when negotiating new agreements and responding to pressures by such countries? Are there any policy recommendations/strategies for developing countries’ negotiators and policymakers?
- Does the Covid-19 pandemic offer new opportunities and challenges for the negotiation dynamics and outcomes?